Prof. Dr. Stuart Maudsley | Pharmacology | Best Researcher Award
Prof. Dr. Stuart Maudsley | Pharmacology – Professor at Moffitt Cancer Center, United States
Dr. Stuart Russell Maudsley is an esteemed researcher and principal investigator whose work has had a profound impact on the field of pharmacology, particularly in the study of G-protein-coupled receptors (GPCRs). His career has been marked by significant contributions to cancer research, aging, and molecular gerontology, leading to the development of innovative therapeutic strategies aimed at treating complex human diseases. Dr. Maudsley’s work focuses on the precision targeting of GPCRs to develop treatments for a wide range of conditions, from cancer to neurodegenerative disorders, with a unique approach that blends basic science with clinical applications. He has been instrumental in leading transformative research at Moffitt Cancer Center and has earned widespread recognition for his contributions in both academia and industry.
Profile:
Scopus
Education:
Dr. Maudsley earned his Ph.D. in Pharmacology from the University of Leeds, UK, after completing a First-Class Bachelor’s degree in Pharmacology at the same institution. His doctoral research focused on electrophysiological and molecular biological studies of Tachykinin receptors, which set the stage for his continued exploration of receptor biology. His academic journey laid the groundwork for a career dedicated to uncovering the complex molecular mechanisms that regulate cellular behavior and how these processes can be manipulated for therapeutic purposes. His early education and research provided a foundation for his later innovations in the field of pharmacology and receptor therapeutics.
Experience:
Dr. Maudsley’s career spans several prestigious roles that highlight his leadership and expertise in pharmacology and receptor biology. He currently serves as the principal investigator at Moffitt Cancer Center, where he directs the Maudsley Lab, focusing on receptor biology and cancer therapeutics. His work is particularly notable for its precision in targeting GPCRs to treat cancer and other complex diseases. Dr. Maudsley also co-founded HeptOME – Receptor Therapeutics, and his position as a Special Science Advisor for the Belgian Superior Health Council reflects his international influence. His experience in both academic and industry settings has allowed him to bridge the gap between cutting-edge research and real-world therapeutic solutions.
Research Interests:
Dr. Maudsley’s primary research interest lies in the molecular and pharmacological study of GPCRs, a class of receptors that play a crucial role in various cellular processes. He focuses on understanding how these receptors regulate human diseases, particularly cancer, aging, and neurodegenerative disorders. By investigating the intricate mechanisms of GPCR signaling, Dr. Maudsley aims to develop novel targeted therapies that can improve treatment outcomes in these complex diseases. His research extends to systems pharmacology, which integrates multidimensional approaches to identify new drug targets and improve therapeutic strategies. Dr. Maudsley is particularly interested in the therapeutic application of GPCR-targeted medicines and their potential to treat diseases with unmet medical needs.
Awards:
Dr. Maudsley has received numerous accolades for his pioneering research in pharmacology and receptor biology. His work has been consistently recognized for its potential to revolutionize therapeutic strategies for cancer and aging-related diseases. He has been invited to speak at prestigious international conferences and has received several awards from scientific and medical societies for his contributions to understanding receptor biology. His recognition as a co-founder of HeptOME – Receptor Therapeutics further highlights his entrepreneurial spirit and ability to translate scientific discoveries into practical applications that benefit patients worldwide.
Publications:
Dr. Maudsley has an extensive publication record, contributing to major scientific journals and collaborative research projects. A few notable publications include:
-
Maudsley S., Leysen H., van Gastel J., Martin B. (2021). Systems Pharmacology: Enabling Multidimensional Therapeutics, Reference Module in Biomedical Sciences. 📖
-
Maudsley S., Schrauwen C., Harputluoğlu İ., Walter D., Leysen H., McDonald P. (2023). GPR19 Coordinates Multiple Molecular Aspects of Stress Responses Associated with the Aging Process, Int J Mol Sci. 🔬
-
Schreurs G., Maudsley S., Nast C., Praet M., Da Silva Fernandes S., Boor P., D’Haese P., De Broe M.E., Vervaet B.A. (2023). Chronic Dehydration Induces Injury Pathways in Rats, Sci Rep. 🧪
-
Maudsley S., Leysen H., Walter D., Vandoren R. (2023). GPCRs Regulate DNA Integrity, Encyclopedia – Biochemistry and Molecular Biology. 📑
-
Coppens V., De Wachter O., Goossens J., Hendrix J., Maudsley S., Azmi A., van Gastel J., Van Saet A., Lauwers T., Morrens M. (2020). Profiling of Peripheral Blood Mononuclear Cells for Schizophrenia Biomarkers, Neuropsychobiology. 🧠
-
Van Meenen J., Leysen H., Chen H., Baccarne R., Walter D., Martin B., Maudsley S. (2022). Making Biomedical Sciences Publications More Accessible for Machines, Med Health Care Philos. 💻
-
Leysen H., Maudsley S., Van Gastel J., Martin B. (2021). The RXFP3 Receptor is a Modulator of Aging-Related Disease, Int J Mol Sci. 🧬
Conclusion:
Dr. Stuart Russell Maudsley’s extensive contributions to pharmacology, especially in the area of GPCRs and their role in complex diseases, make him an exceptional candidate for the Best Researcher Award. His research, which bridges the gap between basic science and clinical applications, continues to shape the future of precision medicine. Through his innovative work at Moffitt Cancer Center and his involvement in entrepreneurial ventures like HeptOME – Receptor Therapeutics, Dr. Maudsley has made a lasting impact on both academia and industry. His leadership in the field and his commitment to advancing therapeutic solutions for cancer, aging, and neurodegenerative diseases position him as a truly deserving nominee for this prestigious award.